[18F]CHDI-650在小鼠体内的生物分布与剂量学用于检测突变亨廷顿蛋白聚集
研究在野生型CD-1瑞士小鼠(每性别n=15)中评估新型氟化突变亨廷顿蛋白放射性配体[18F]CHDI-650的体内PET成像与离体生物分布,并将数据外推至人体模型计算剂量。OLINDA基于体内数据的总平均有效剂量为21.7 μSv/MBq,最高器官当量剂量在膀胱壁为4.52 μSv/MBq;离体基于总平均有效剂量为20.6 μSv/MBq,膀胱壁最高为4.22 μSv/MBq。作者认为吸收剂量和有效剂量远低于推荐限值,提示该放射性配体适合临床评估,基于最高有效剂量估计人体注射370 MBq将产生8.03 mSv辐射剂量。
要点
- 小鼠体内PET与离体生物分布显示[18F]CHDI-650在多数器官30分钟后快速清除,胆囊和尿液摄取最高。
- OLINDA基于体内数据总平均有效剂量21.7 μSv/MBq,膀胱壁当量剂量最高为4.52 μSv/MBq。
- 离体基于总平均有效剂量20.6 μSv/MBq,膀胱壁最高当量剂量4.22 μSv/MBq;IDAC-Dose与OLINDA相关性r=0.9320和r=0.9368。
核心结论
- 剂量学分析表明[18F]CHDI-650的吸收剂量和有效剂量远低于推荐限值,提示该放射性配体适合临床评估。
- 基于最高有效剂量估计,人体注射370 MBq将产生8.03 mSv的辐射剂量。
研究设计与样本
- 使用野生型雄性及雌性CD-1瑞士小鼠(每性别n=15)评估[18F]CHDI-650在注射后30、60、120、240和360分钟的体内PET成像与离体生物分布。
主要发现
- 离体和PET成像生物分布显示[18F]CHDI-650在大多数器官30分钟后快速清除,小鼠中胆囊和尿液摄取最高。
- OLINDA外推至人体模型显示基于体内数据的总平均有效剂量为21.7 μSv/MBq,最高器官当量剂量在膀胱壁为4.52 μSv/MBq。
- 基于离体数据的总平均有效剂量为20.6 μSv/MBq,膀胱壁最高当量剂量估计为4.22 μSv/MBq。
- 使用IDAC-Dose预测的人体暴露与OLINDA在体内和离体测量中均相关性良好(r=0.9320和r=0.9368)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related neuropathophysiology. Noninvasive visualization of mHTT aggregates in the brain, with positron emission tomography (PET), will allow to reliably evaluate the efficacy of therapeutic interventions in HD. This study aimed to assess the radiation burden of [18F]CHDI-650, a novel fluorinated mHTT radioligand, in humans based on both in vivo and ex vivo biodistribution in mice and subsequent determination of dosimetry for dosing in humans. RESULTS: Wild-type male and female CD-1 Swiss mice (n = 15/sex) were used to assess in vivo PET imaging-based and ex vivo biodistribution-based tracer distribution of [18F]CHDI-650 at 30-, 60-, 120-, 240- and 360-min post-injection. Three-dimensional volumes of interest of the organs were drawn on the co-registered PET/CT image and organs were collected after dissection. Organ radioactivity levels were determined using both modalities. The residence time was calculated and extrapolated to human phantoms. The absorbed and effective doses were computed with OLINDA/EXM 2.2 and IDAC-Dose2.1. Ex vivo and PET-imaging biodistribution of [18F]CHDI-650 showed rapid washout after 30 min in most of the organs with the highest uptake in the gallbladder and urine in mice. Extrapolation of the data to human phantoms with OLINDA showed a total mean in vivo based effective dose of 21.7 μSv/MBq with the highest equivalent organ dose in the urinary bladder wall (4.52 μSv/MBq). The total mean ex vivo based effective dose was calculated to be 20.6 μSv/MBq. The highest equivalent organ dose ex vivo in the urinary bladder wall was estimated to be 4.22 μSv/MBq. The predicted exposure in humans using IDAC-Dose correlated well to those obtained with OLINDA for both in vivo and ex vivo measurements (r = 0.9320 and r = 0.9368, respectively). CONCLUSIONS: Dosimetry analysis indicated absorbed and effective doses of [18F]CHDI-650 are well below the recommended limits, suggesting that the radioligand is suitable for clinical assessment. Based on the highest effective dose estimates, an injection of 370 MBq in humans would result in a radiation dose of 8.03 mSv.
引用
- Akkermans J, Miranda A, Verhaeghe J, et al. Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates. EJNMMI Res. 2024. PMID: 39729164. doi:10.1186/s13550-024-01188-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。